| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ferdinand Roelfsema, Simon Kok, Petra Kok, Alberto M Pereira, Nienke R Biermasz, Jan W Smit, Marijke Frolich, Daniel M Keenan, Johannes D Veldhuis, Johannes A Romij. Pituitary-hormone secretion by thyrotropinomas. Pituitary. vol 12. issue 3. 2009-10-20. PMID:19051037. |
increased concentrations of growth hormone (gh) or prolactin (prl) are observed in about 30% of thyrotropinomas leading to acromegaly or disturbed sexual functions beyond thyrotropin (tsh)-induced hyperthyroidism. |
2009-10-20 |
2023-08-12 |
Not clear |
| Ferdinand Roelfsema, Simon Kok, Petra Kok, Alberto M Pereira, Nienke R Biermasz, Jan W Smit, Marijke Frolich, Daniel M Keenan, Johannes D Veldhuis, Johannes A Romij. Pituitary-hormone secretion by thyrotropinomas. Pituitary. vol 12. issue 3. 2009-10-20. PMID:19051037. |
although only one patient had clinical acromegaly, gh secretion and igf-i levels were increased in two other patients and all three had a significant cross-correlation between the gh and tsh. |
2009-10-20 |
2023-08-12 |
Not clear |
| Magdalena Jaskula, Ryszard Wasko, Hanna Komarowska, Aleksandra Dziubandowska, Jerzy Sowinsk. Serum ghrelin levels and disturbances of the lipid profile in patients with acromegaly. Neuro endocrinology letters. vol 30. issue 2. 2009-10-20. PMID:19675514. |
2) assess the correlations between concentrations of ghrelin and concentrations of gh, igf-1, cholesterol, insulin and glucose in patients with acromegaly. |
2009-10-20 |
2023-08-12 |
Not clear |
| Daniela Fedrizzi, Mauro Antonio Czepielewsk. [Cardiovascular disturbances in acromegaly]. Arquivos brasileiros de endocrinologia e metabologia. vol 52. issue 9. 2009-10-16. PMID:19197449. |
acromegaly causes a number of disorders in the cardiovascular system, resulting from chronic exposure to high levels of gh and igf-1. |
2009-10-16 |
2023-08-12 |
Not clear |
| M Sherlock, A Aragon Alonso, R C Reulen, J Ayuk, R N Clayton, G Holder, M C Sheppard, A Bates, P M Stewar. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clinical endocrinology. vol 71. issue 1. 2009-10-13. PMID:19178529. |
monitoring disease activity using gh and igf-i in the follow-up of 501 patients with acromegaly. |
2009-10-13 |
2023-08-12 |
Not clear |
| K Mullan, C Sanabria, W P Abram, E M McConnell, H C Courtney, S J Hunter, D R McCance, H Leslie, B Sheridan, A B Atkinso. Long term effect of external pituitary irradiation on IGF1 levels in patients with acromegaly free of adjunctive treatment. European journal of endocrinology. vol 161. issue 4. 2009-10-05. PMID:19661126. |
it is established that external pituitary irradiation (epi) effectively reduces serum gh levels in acromegaly. |
2009-10-05 |
2023-08-12 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Alberto Rebora, Mariano Galdiero, Eugenia Resmini, Francesco Minuto, Gaetano Lombardi, Rosario Pivonello, Diego Feron. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clinical endocrinology. vol 71. issue 2. 2009-09-28. PMID:19094074. |
to evaluate gh and igf-i control and tumour shrinkage in newly diagnosed patients with acromegaly treated first-line with lanreotide-autogel (atg) 120 mg. design open, prospective. |
2009-09-28 |
2023-08-12 |
Not clear |
| Pamela U Fred. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clinical endocrinology. vol 71. issue 2. 2009-09-28. PMID:19226264. |
monitoring of acromegaly: what should be performed when gh and igf-1 levels are discrepant? |
2009-09-28 |
2023-08-12 |
Not clear |
| Pamela U Fred. Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant? Clinical endocrinology. vol 71. issue 2. 2009-09-28. PMID:19226264. |
monitoring of a patient with acromegaly requires periodic evaluation of levels of gh and igf-1, the biochemical markers of this disease. |
2009-09-28 |
2023-08-12 |
Not clear |
| Marily Theodoropoulou, Maria A Tichomirowa, Caroline Sievers, Alexander Yassouridis, Thomas Arzberger, Olivier Hougrand, Manuel Deprez, Adrian F Daly, Patrick Petrossians, Uberto Pagotto, Albert Beckers, Günter K Stall. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. International journal of cancer. vol 125. issue 9. 2009-09-15. PMID:19637311. |
the aim of the present retrospective cohort study was to determine whether zac1 immunoreactivity in archival somatotrophinoma tissue derived from 45 patients with acromegaly routinely pretreated with ssa before surgery, was associated with response to ssa (normalization of gh, igf-i and presence of tumor shrinkage). |
2009-09-15 |
2023-08-12 |
Not clear |
| Maximilian Bielohuby, Josefine Roemmler, Jenny Manolopoulou, Inga Johnsen, Mandy Sawitzky, Jochen Schopohl, Martin Reincke, Eckhard Wolf, Andreas Hoeflich, Martin Bidlingmaie. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. Experimental biology and medicine (Maywood, N.J.). vol 234. issue 8. 2009-09-10. PMID:19491373. |
acromegaly is a disease characterized by chronic growth hormone (gh) excess. |
2009-09-10 |
2023-08-12 |
mouse |
| Maximilian Bielohuby, Josefine Roemmler, Jenny Manolopoulou, Inga Johnsen, Mandy Sawitzky, Jochen Schopohl, Martin Reincke, Eckhard Wolf, Andreas Hoeflich, Martin Bidlingmaie. Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice. Experimental biology and medicine (Maywood, N.J.). vol 234. issue 8. 2009-09-10. PMID:19491373. |
since hypertension is a common finding in patients with acromegaly, interactions between gh and the renin-angiotensin-aldosterone system (raas) are under controversial debate. |
2009-09-10 |
2023-08-12 |
mouse |
| Danilo Lopes Ferreira Lima, Renan Magalhães Montenegro, Anya Pimentel Gomes Fernandes Vieira, Mônica Fiterman Albano, Delane Maria Reg. Absence of periodontitis in acromegalic patients. Clinical oral investigations. vol 13. issue 2. 2009-09-01. PMID:18766388. |
acromegaly is a metabolic disorder caused by increased growth hormone (gh) secretion. |
2009-09-01 |
2023-08-12 |
human |
| Masanori Yamazaki, Ai Sato, Shin-ichi Nishio, Teiji Takeda, Takahide Miyamoto, Miyuki Katai, Kiyoshi Hashizum. Acromegaly accompanied by Turner syndrome with 47,XXX/45,X/46,XX mosaicism. Internal medicine (Tokyo, Japan). vol 48. issue 6. 2009-08-25. PMID:19293545. |
a pituitary adenoma with elevated serum levels of growth hormone (gh) and insulin-like growth factor-i (igf-i) was detected, indicating acromegaly caused by gh-secreting pituitary adenoma. |
2009-08-25 |
2023-08-12 |
Not clear |
| Pamela U Freda, Wei Shen, Carlos M Reyes-Vidal, Eliza B Geer, Fernando Arias-Mendoza, Dympna Gallagher, Steven B Heymsfiel. Skeletal muscle mass in acromegaly assessed by magnetic resonance imaging and dual-photon x-ray absorptiometry. The Journal of clinical endocrinology and metabolism. vol 94. issue 8. 2009-08-25. PMID:19491226. |
gh and igf-i are nitrogen retaining and anabolic, but the impact of long-term exposure to supraphysiological gh and igf-i, either from endogenous overproduction in acromegaly or exogenous sources, on skeletal muscle (sm) mass is not clear. |
2009-08-25 |
2023-08-12 |
Not clear |
| Vita Birzniece, Akira Sata, Ken K Y H. Growth hormone receptor modulators. Reviews in endocrine & metabolic disorders. vol 10. issue 2. 2009-08-24. PMID:18622706. |
pegylation of a gh analogue (pegvisomant) which binds but not activate signal transduction forms the basis of a new successful approach to the treatment of acromegaly. |
2009-08-24 |
2023-08-12 |
Not clear |
| Albert A Edwards, Francesca M Swords, P N Plowma. Focal radiation therapy for patients with persistent/recurrent pituitary adenoma, despite previous radiotherapy. Pituitary. vol 12. issue 1. 2009-08-21. PMID:18437578. |
with careful case selection, we here demonstrate that in acromegaly, for example, normalisation of both gh and igf levels may be achieved in 37-58% of these previously irradiated patients with low risk of late morbidity. |
2009-08-21 |
2023-08-12 |
Not clear |
| Jackson A Gondim, Tania Ferraz, Italo Mota, Dayse Studart, João P C Almeida, Erika Gomes, Michele Schop. Outcome of surgical intrasellar growth hormone tumor performed by a pituitary specialist surgeon in a developing country. Surgical neurology. vol 72. issue 1. 2009-08-17. PMID:18440607. |
acromegaly is an excessive gh secretion, which in most cases, is caused by a pituitary gh-secreting adenoma. |
2009-08-17 |
2023-08-12 |
Not clear |
| J Roemmler, B Steffin, B Gutt, C Sievers, M Bidlingmaier, J Schopoh. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 19. issue 3. 2009-08-13. PMID:19109045. |
the effect of acute application of pegvisomant alone and in combination with octreotide on endogenous gh levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. |
2009-08-13 |
2023-08-12 |
Not clear |
| Peter Kamenicky, Christine Dos Santos, Consuelo Espinosa, Sylvie Salenave, Françoise Galland, Yves Le Bouc, Patrick Maison, Pierre Bougnères, Philippe Chanso. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly. European journal of endocrinology. vol 161. issue 2. 2009-08-12. PMID:19439509. |
d3 gh receptor polymorphism is not associated with igf1 levels in untreated acromegaly. |
2009-08-12 |
2023-08-12 |
Not clear |